EMERYVILLE, Calif., May 09, 2017 -- Amyris, Inc. (Nasdaq:AMRS) today announced that it will host its 1st Annual Biotech Summit on Tuesday, May 16, 2017 at its headquarters in Emeryville detailing for partners, customers and investors how industrial biotech is disrupting high growth markets. The company plans to videocast a portion of the event, including formal presentations and panel discussions, starting at approximately 12:00 p.m. Eastern Time and concluding at approximately 2:00 p.m. Eastern Time.
During the Investor Day portion of the event, the company will review details related to its revenue plans, product and market performance and detail its customer and partner relationships. This will include an update regarding the expected accretive contribution to revenue from the DSM relationship announced yesterday. This will also include a detailed review of the successful partnership with Nenter for Vitamin E and the record growth in Biossance product sales. The company will detail the planned use of proceeds from the majority of the funds expected from the recently announced funding applied to support its strong growth.
Following these sessions, onsite attendees will then participate in an exclusive look into Amyris’s labs hosted by members of the company’s senior research & development team followed by a networking lunch.
Videocast:
A live videocast of the event will be available online on the Amyris website. To access the live videocast, please visit: http://investors.amyris.com. A replay of the videocast will be available on the Investor Relations section of the Company's website approximately two hours after the conclusion of the presentations and panel discussions.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the expected impact from the recently announced relationship with DSM and the anticipated closing of a recently announced financing transaction) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 [email protected] [email protected]


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Instagram Outage Disrupts Thousands of U.S. Users 



